Please login to the form below

Not currently logged in
Email:
Password:

EMD Serono

This page shows the latest EMD Serono news and features for those working in and with pharma, biotech and healthcare.

Regeneron top science employer, says survey

Regeneron top science employer, says survey

20. -. Merck KGaA/Merck Serono/EMD Serono. Respondents indicated that being an innovation leader was the most important driver in choosing companies, but this year's survey also revealed that employees

Latest news

  • This month in 1917: A tale of two Mercks This month in 1917: A tale of two Mercks

    E. Merck went on to assume the Merck KGaA name outside the US and Canada, as well as choosing to go by EMD (E. ... US and Canada, comprising the biopharma business EMD Serono and the life science tools business EMD Millipore.

  • Merck KGaA and Pfizer collaborate on lupus Merck KGaA and Pfizer collaborate on lupus

    Germany-based Merck KGaA – via its stateside subsidiary EMD Serono – and US-based Pfizer have signed an agreement with the Broad Institute, a non-profit research organisation affiliated with both the

  • FDA clears six new drugs in time for the new year FDA clears six new drugs in time for the new year

    The drug will compete in the US market with two other SBS treatments, namely EMD Serono's Zorbtive (somatropin) and Emmaus Medical's Nutrestore (glutamine). .

  • Digital Intelligence roundup

    Merck Serono has increased its digital outputs over the last few months, launching Twitter accounts for both its German operations and its EMD Serono US division in May. ... Meanwhile, EMD Serono has also joined the handful of pharmaceutical companies

  • Ferrer pulls EU application for Egrifta in HIV patients with excess tissue

    It is marketed in the country by EMD Serono, an affiliate of Germany's Merck KGaA, who bought regional rights to the drug from its original developers Theratechnologies in a deal ... EMD Serono also has an option to participate in future indications in

More from news
Approximately 1 fully matching, plus 19 partially matching documents found.

Latest appointments

  • The Medicines Company strengthens board of directors The Medicines Company strengthens board of directors

    Prior to joining ARIAD, Panayiotopoulos served as president of EMD Serono - the North American biopharmaceutical business of Merck KGaA - after serving as president of Merck Serono, Tokyo.

  • Former Novartis exec Richard Smith joins EMD Serono Former Novartis exec Richard Smith joins EMD Serono

    Former Novartis exec Richard Smith joins EMD Serono. He becomes senior vice president and head of US fertility and endocrinology. ... Merck KGaA's US biopharmaceutical business EMD Serono has appointed Richard Smith as senior vice president and head of

  • EMD Serono appoints neurology and immunology SVP EMD Serono appoints neurology and immunology SVP

    EMD Serono appoints neurology and immunology SVP. Promotes head of US Fertility and Endocrinology Craig Millian. ... Gary Zieziula, president and managing director of EMD Serono, said: “ Craig is a dynamic leader with a proven track record of success.

  • EMD Serono president James Hoyes joins consultants RxC EMD Serono president James Hoyes joins consultants RxC

    EMD Serono president James Hoyes joins consultants RxC. Takes up a role as executive partner at the US management consulting firm. ... Prior to joining EMD Serono, Hoyes held leadership positions with the likes of Serono, Elan and Sanofi.

  • Merck appoints new North America and China biopharma leaders Merck appoints new North America and China biopharma leaders

    Zieziula (pictured right) has been appointed president and managing director for Merck's North American biopharma, EMD Serono, replacing Paris Panayiotopoulos with immediate effect.

More from appointments
Approximately 4 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics